Bo Liang

Form D signer

Bo Liang

Chief Executive Officer at IVIEW Therapeutics

Form D signer

Capital raised by IVIEW Therapeutics

$9.2M+$9.2M latest round

2 Form D filings · first filed May 2024 · Cranbury, NJ

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 1 ↗

Career

1 company on file

IVIEW TherapeuticsBiotech · Cranbury, NJsince May 2024

Chief Executive Officer

Signatory on IVIEW Therapeutics's Form D filings · $9.2M raised across 2

Company filings

via EDGAR · Form D for IVIEW Therapeutics2

DateCompanyFormAmountRole on filing

May 14, 2024IVIEW TherapeuticsForm D/A+$9.2MChief Executive Officer

Form D/AMay 14, 2024 · IVIEW Therapeutics+$9.2Mas Chief Executive Officer

May 14, 2024IVIEW TherapeuticsForm D/A+$7.7MChief Executive Officer

Form D/AMay 14, 2024 · IVIEW Therapeutics+$7.7Mas Chief Executive Officer

Overview

Last filing May 14, 2024

Bo Liang is on file as Chief Executive Officer at IVIEW Therapeutics in Cranbury, NJ. IVIEW Therapeutics has 2 Form D filings on record, $9.2M raised in total. Bo Liang appears as a signatory on the company's filings.

Teammates

IVIEW Therapeutics · 1

Xiaolu SunDirector

Products

IVIEW Therapeutics · 1

IVW-1001Ocular treatment

IVW-1001 is a novel TRPM8 agonist specifically designed for the treatment of dry eye disease. This innovative product is delivered via an ophthalmic eyelid wipe, ensuring both ease of use and targeted action directly at the affected area.